Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes®, is an activated platelet-based hemostatic agent. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. Thrombosomes® has also been given orphan drug designation for the treatment of Acute Radiation Sickness by the U.S. Food and Drug Administration.
Cellphire is identifying and developing other novel cellular-based therapies to address unmet needs. We're researching transformative roles for platelets in anti-thrombotic reversal and regenerative medicine, among others.
To learn more about the thinking behind our science, click here.
Prior Phase 1 safety studies support all Thrombosomes® indications.
Submission for approval for ARS would be under the Animal Rule; human Phase 1 studies provide safety data in support of the Animal Rule.